Dr Reddy's Laboratories reports 2% rise in Q1 net profit to Rs. 1,418 Cr
Revenue increased 11.4 per cent to Rs. 8,545 crore
Revenue increased 11.4 per cent to Rs. 8,545 crore
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats
Upgrades 2025 full-year CDMO sales and margin outlook
Shelcal Total marks the brand’s evolution into a modern, consumer-focused nutrition portfolio
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
The campaign celebrates radiant, healthy skin that shines naturally, empowering women to step forward with confidence in every walk of life.
Celecoxib is a nonsteroidal anti-inflammatory drug
Subscribe To Our Newsletter & Stay Updated